Related Experiment Videos
Chapter 6: Immunosuppression and co-infection with HIV
Joel M Palefsky1, Elizabeth A Holly
1University of California-San Francisco, 505 Parnassus Ave., Rm. M1203, Box 0126, San Francisco, CA 94143, USA. joelp@medicine.ucsf.edu
Journal of the National Cancer Institute. Monographs
|June 17, 2003
Summary
Immunosuppression increases the risk of human papillomavirus (HPV)-associated cancers, particularly in early dysplasia stages. Further research is needed to understand HPV biology in immunocompromised individuals.
Area of Science:
- Immunology
- Oncology
- Virology
Background:
- Individuals with HIV or organ transplants face higher risks of HPV-associated anogenital cancers.
- The precise mechanisms by which immunosuppression elevates cancer risk are not fully understood.
- Current data suggest immunosuppression impacts early dysplasia more than cancer progression.
Purpose of the Study:
- To explore the biology of HPV infection in immunocompromised populations.
- To investigate the role of immunosuppression in HPV-associated dysplasia and cancer.
- To identify knowledge gaps regarding HPV in HIV-positive and HIV-negative immunocompromised individuals.
Main Methods:
- Review of existing literature on HPV infection and immunosuppression.
- Analysis of data on dysplasia and cancer progression in immunocompromised cohorts.
- Discussion of biomarker limitations for HPV-specific cell-mediated immunity.
Main Results:
- Immunosuppression is strongly linked to early-stage HPV-associated dysplasia.
- Progression to invasive cancer is not directly associated with immunosuppression.
- Biomarkers for HPV immune response are scarce, hindering detailed studies.
Conclusions:
- Understanding HPV in immunocompromised individuals can illuminate its role in the general population.
- Further research is required on HPV in HIV-negative transplant recipients versus HIV-positive individuals.
- The impact of antiretroviral therapy on HPV natural history warrants investigation.